

Luca Castagna

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5382081/luca-castagna-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

4,855
citations

34
h-index

57
g-index

272
ext. papers

5,879
ext. citations

3.9
avg, IF

4.94
L-index

#	Paper	IF	Citations
244	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 119, 1599-606	2.2	191
243	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin lymphoma. <i>Haematologica</i> , 2007 , 92, 35-41	6.6	169
242	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017 , 129, 1380-1388	2.2	167
241	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010 , 115, 3671-7	2.2	129
240	Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 724-9	4.7	120
239	Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1904-11	4.4	117
238	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015 , 125, 2855-64	2.2	100
237	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3425-3432	2.2	100
236	Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. <i>Transplant Infectious Disease</i> , 2015 , 17, 242-9	2.7	96
235	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 521-534	4.4	94
234	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin lymphoma responding to prior salvage therapy. <i>Haematologica</i> , 2012 , 97, 1073-9	6.6	88
233	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009 , 113, 3375-82	2.2	81
232	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. <i>Cancer</i> , 2018 , 124, 1428-1437	6.4	78
231	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 119-24	4.7	74
230	Identification of prognostic factors predicting outcome in Hodgkin lymphoma patients relapsing after autologous stem cell transplantation. <i>Annals of Oncology</i> , 2013 , 24, 2430-4	10.3	74
229	Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 736-9	2.2	74
228	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3233-9	2.2	66

227	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1884-1896	11.6	63
226	High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2181-8	2.2	60
225	The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. <i>Bone Marrow Transplantation</i> , 2012 , 47, 639-45	4.4	59
224	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019 , 3, 360-369	7.8	59
223	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. <i>Annals of Hematology</i> , 2012 , 91, 931-9	3	56
222	Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. <i>Cancer</i> , 2013 , 119, 602-11	6.4	55
221	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. <i>Cancer</i> , 2013 , 119, 986-92	6.4	51
220	Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect?. <i>Therapeutic Apheresis and Dialysis</i> , 2007 , 11, 85-93	1.9	50
219	Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. <i>Leukemia</i> , 2015 , 29, 686-8	10.7	48
218	The early expansion of anergic NKG2A/CD56/CD16 natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. <i>Haematologica</i> , 2018 , 103, 1390-1402	6.6	47
217	Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. <i>British Journal of Haematology</i> , 2009 , 145, 369-72	4.5	46
216	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 12-24	4.4	46
215	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1475-80	4.4	38
214	Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 370-4	4.7	37
213	Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. <i>Annals of Oncology</i> , 2001 , 12, 953-5	10.3	36
212	Donor lymphocyte infusion after allogeneic stem cell transplantation. <i>Transfusion and Apheresis Science</i> , 2016 , 54, 345-55	2.4	36
211	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K/Inhibitor RP6530. <i>Clinical Cancer Research</i> , 2019 , 25, 1098-1112	12.9	35
210	Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. <i>Experimental Hematology</i> , 2012 , 40, 521-7	3.1	33

209	Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. <i>Experimental Hematology</i> , 2010 , 38, 1241-50	3.1	33
208	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. <i>Leukemia</i> , 2016 , 30, 2086-2089	10.7	33
207	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017 , 52, 683-688	4.4	32
206	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1599-1601	4.4	32
205	T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 627-632	4.7	32
204	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , 2016 , 27, 2251-2257	10.3	31
203	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013 , 27, 2086-91	10.7	31
202	Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010 , 116, 5001-11	6.4	30
201	Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. <i>Bone Marrow Transplantation</i> , 2011 , 46, 1000-5	4.4	29
200	Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease. <i>Transplantation</i> , 1997 , 63, 1307-13	1.8	29
199	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. <i>Cancer</i> , 2015 , 121, 1809-16	6.4	28
198	Primary refractory and early-relapsed Hodgkin lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. <i>Journal of Pathology</i> , 2015 , 237, 4-13	9.4	28
197	Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 549-554	4.7	26
196	Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. <i>Oncologist</i> , 2015 , 20, 323-8	5.7	25
195	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1449-1454	4.7	25
194	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. <i>Annals of Oncology</i> , 2016 , 27, 1088-1094	10.3	25
193	Interplay effects between dose distribution quality and positioning accuracy in total marrow irradiation with volumetric modulated arc therapy. <i>Medical Physics</i> , 2013 , 40, 111713	4.4	25
192	Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. <i>British Journal of Cancer</i> , 2003 , 89, 1159-61	8.7	25

191	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020 , 105, 47-58	6.6	25
190	Plan robustness in field junction region from arcs with different patient orientation in total marrow irradiation with VMAT. <i>Physica Medica</i> , 2015 , 31, 677-82	2.7	24
189	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 46	22.4	24
188	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. <i>Haematologica</i> , 2014 , 99, 1762-8	6.6	24
187	Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1026-32	4.7	24
186	Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 432-8	4.7	24
185	Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients. <i>American Journal of Hematology</i> , 2006 , 81, 1-4	7.1	24
184	Do different conditioning regimens really make a difference?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 237-245	3.1	23
183	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017 , 52, 689-696	4.4	22
182	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. <i>Haematologica</i> , 2015 , 100, 269-74	6.6	22
181	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1549-1554	4.7	21
180	National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1106-12	1.9	21
179	Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin lymphoma: a monocenter prospective study. <i>American Journal of Hematology</i> , 2007 , 82, 122-7	7.1	21
178	Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. <i>Annals of Oncology</i> , 2002 , 13, 1341-6	10.3	21
177	Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. <i>Oncogene</i> , 2000 , 19, 2758-66	9.2	21
176	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1032-40	4.4	21
175	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <i>American Journal of Hematology</i> , 2014 , 89, 83-7	7.1	20
174	Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2012 , 87, 1074-8	7.1	20

173	Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. <i>British Journal of Cancer</i> , 2013 , 109, 2523-32	8.7	20
172	Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2001 , 28, 923-7	4.4	20
171	Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit. <i>Journal of Critical Care</i> , 2015 , 30, 1107-13	4	19
170	Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. <i>Journal of Applied Clinical Medical Physics</i> , 2012 , 13, 3653	2.3	19
169	Vertebroplasty for pain relief and spinal stabilization in multiple myeloma. <i>Neurological Sciences</i> , 2010 , 31, 151-7	3.5	19
168	Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin disease after high-dose chemotherapy and autologous stem cell infusion. <i>European Journal of Haematology</i> , 2007 , 78, 322-9	3.8	19
167	Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. <i>Bone Marrow Transplantation</i> , 2005 , 35, 1225	4.4	19
166	Bendamustine combined with donor lymphocytes infusion in Hodgkin lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1444-7	4.7	18
165	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 940-8	4.7	17
164	The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1134-6	4.4	17
163	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017 , 52, 955-961	4.4	16
162	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. <i>Bone Marrow Transplantation</i> , 2017 , 52, 620-621	4.4	16
161	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1518-1526	2.2	16
160	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. <i>American Journal of Hematology</i> , 2018 , 93, 769-777	7.1	16
159	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2016 , 51, 194-8	4.4	16
158	Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. <i>Annals of Oncology</i> , 2010 , 21, 1482-1485	10.3	16
157	Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1705-10	1.9	16
156	Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2010 , 3, 167-73	2.7	16

155	IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin lymphoma patients. <i>Bone Marrow Transplantation</i> , 2007 , 40, 1019-25	4.4	16
154	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1067-1076	4.4	16
153	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1730-1737	4.4	15
152	Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1395-1406	4.7	15
151	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 422-430	4.4	15
150	High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. <i>American Journal of Hematology</i> , 2018 , 93, 10-16	7.1	15
149	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1449-62	5.4	15
148	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021 , 35, 2672-2683	6.8	15
147	Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor. <i>Journal of Clinical Virology</i> , 2016 , 84, 24-26	14.5	15
146	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018 , 181, 86-96	4.5	14
145	Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2013 , 48, 249-52	4.4	14
144	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. <i>Bone Marrow Transplantation</i> , 2013 , 48, 414-8	4.4	14
143	Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. <i>Experimental Hematology</i> , 2011 , 39, 892-6	3.1	14
142	Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin lymphoma: survey from a single institution. <i>American Journal of Hematology</i> , 2003 , 73, 267-72	7.1	14
141	Do different conditioning regimens really make a difference?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 237-45	3.1	14
140	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1915-1922	4.7	14
139	In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study. <i>Radiation Oncology</i> , 2015 , 10, 86	4.2	13
138	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1522-1531	4.4	13

137	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012 , 26, 1779-85	10.7	13
136	Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. <i>Leukemia and Lymphoma</i> , 2009 , 50, 80-4	1.9	13
135	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007 , 92, 418-20	6.6	13
134	Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1096-1104	4.4	12
133	The novel PI3K- γ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. <i>Leukemia</i> , 2016 , 30, 2402-2405	10.7	12
132	Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation. <i>Scientific Reports</i> , 2016 , 6, 35745	4.9	12
131	Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients. <i>British Journal of Haematology</i> , 2017 , 176, 132-135	4.5	12
130	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1505-15	5.4	12
129	Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen. <i>Annals of Oncology</i> , 2003 , 14, 959-60	10.3	12
128	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020 , 4, 3900-3912	7.8	12
127	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 136-140	7.8	12
126	Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2012 , 88, 497-503	3.8	11
125	Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013 , 5, e2013026	3.2	11
124	Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1085-91	4.7	11
123	Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. <i>Oncology</i> , 1993 , 50 Suppl 2, 47-52	3.6	11
122	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019 , 125, 90-98	6.4	11
121	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021 , 96, 69-79	7.1	11
120	Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1810-1817	4.7	10

119	Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 cells. <i>British Journal of Haematology</i> , 2019 , 185, 570-573	4.5	10
118	Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1560-5	4.7	10
117	The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2017 , 52, 135-137	4.4	10
116	Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015 , 7, e2015015	3.2	10
115	Maintained all-trans retinoic acid therapy in a patient with pseudotumour cerebri despite aggravated symptoms. <i>Leukemia and Lymphoma</i> , 1997 , 27, 373-4	1.9	10
114	Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). <i>British Journal of Haematology</i> , 1998 , 103, 284-5	4.5	10
113	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. <i>Cancer Medicine</i> , 2020 , 9, 52-61	4.8	10
112	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. <i>British Journal of Haematology</i> , 2020 , 188, 745-756	4.5	10
111	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 1242-1249	7.8	10
110	High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. <i>Annals of Oncology</i> , 2006 , 17, 174-6	10.3	9
109	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 936-942	4.7	9
108	Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. <i>Bone Marrow Transplantation</i> , 2015 , 50, 865-7	4.4	8
107	B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. <i>Bone Marrow Transplantation</i> , 2015 , 50, 317-9	4.4	8
106	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 255-263	4.4	8
105	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. <i>Bone Marrow Transplantation</i> , 2015 , 50, 499-504	4.4	8
104	High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin. <i>British Journal of Haematology</i> , 2005 , 129, 709-10	4.5	8
103	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 349-355	4.4	8
102	First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY. <i>Bone Marrow Transplantation</i> , 2014 , 49, 317-8	4.4	7

101	Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 501-6	4.7	7
100	ECIL 3-2009 update guidelines for antifungal management. <i>Bone Marrow Transplantation</i> , 2012 , 47, 866	4.4	7
99	Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. <i>Bone Marrow Transplantation</i> , 2002 , 30, 207-14	4.4	7
98	Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas. <i>Bone Marrow Transplantation</i> , 2005 , 35, 421-2	4.4	7
97	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation. <i>Transfusion</i> , 2016 , 56, 1096-1100	2.9	7
96	TLI in refractory chronic GVHD. <i>Bone Marrow Transplantation</i> , 2013 , 48, 854-8	4.4	6
95	Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015 , 7, e2015048	3.2	6
94	Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 794-8	4.4	6
93	Parvovirus B19 as an etiological agent of acute pleuro-pericarditis. <i>Bone Marrow Transplantation</i> , 2011 , 46, 317-8	4.4	6
92	Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1015-8	1.9	6
91	Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications. <i>Supportive Care in Cancer</i> , 2006 , 14, 1141-6	3.9	6
90	High-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly versus younger lymphoma patients: a matched analysis. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1439-40	1.9	6
89	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. <i>Blood</i> , 2016 , 128, 1165-1165	2.2	6
88	Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma. <i>Oncotarget</i> , 2018 , 9, 22741-22748	3.3	6
87	Development of an Immobilization Device for Total Marrow Irradiation. <i>Practical Radiation Oncology</i> , 2021 , 11, e98-e105	2.8	6
86	Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>European Journal of Haematology</i> , 2019 , 102, 357-367	3.8	5
85	Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. <i>Experimental Hematology</i> , 2013 , 41, 17-27	3.1	5
84	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015 , 100, e423-7	6.6	5

83	JC Virus Leuko-Encephalopathy in Reduced Intensity Conditioning Cord Blood Transplant Recipient with a Review of the Literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012 , 4, e2012043	3.2	5
82	Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1630-2	1.9	5
81	Neutropenic Enterocolitis: Is There Aright Timing for Surgery? Assessment of a Clinical Case. <i>Tumori</i> , 2007 , 93, 608-610	1.7	5
80	CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. <i>European Journal of Haematology</i> , 2007 , 78, 111-6	3.8	5
79	Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen. <i>Bone Marrow Transplantation</i> , 2004 , 33, 1067-8	4.4	5
78	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019 , 134, 775-775	2.2	5
77	Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 115-124		5
76	Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 617-623 ²		4
75	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016 , 51, 462-5	4.4	4
74	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m ² intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2315-20	1.9	4
73	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2063-5	1.9	4
72	Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?. <i>Oncologist</i> , 2004 , 9, 594-5; author reply 596 ⁵⁻⁷		4
71	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020 , 20, 1140	4.8	4
70	Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. <i>JCI Insight</i> , 2021 , 6,	9.9	4
69	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2763-2770	4.4	4
68	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 821-836	5.4	3
67	Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2514-2516	4.7	3
66	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1164-1167	4.4	3

65	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 296-304	2	3
64	Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1644-1646	4.4	3
63	Bone marrow donor-related variables associated with harvest outcome in HLA-haploidentical transplantation with postinfusion cyclophosphamide. <i>Vox Sanguinis</i> , 2016 , 111, 93-100	3.1	3
62	Rituximab in thrombotic microangiopathy. <i>British Journal of Haematology</i> , 2007 , 139, 166; author reply 166-7	4.5	3
61	Primary mediastinal B-cell lymphoma with sclerosis: report of 11 cases treated with intensified-CHOP plus radiotherapy. <i>American Journal of Hematology</i> , 2005 , 78, 312-3	7.1	3
60	Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia: graft-versus-leukemia effect without graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001 , 28, 1155-6	4.4	3
59	What is the best option to cure patients with resistant/relapsing Hodgkin disease?. <i>Current Stem Cell Research and Therapy</i> , 2006 , 1, 419-24	3.6	3
58	T-cell-replete haploidentical transplantation in acute myeloid leukemia. <i>Experimental Hematology</i> , 2018 , 58, 5-16	3.1	3
57	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT.. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, S242-S243	4.7	2
56	A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. <i>Transplant Infectious Disease</i> , 2018 , 20, e12906	2.7	2
55	Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2013 , 41, 503-5	3.1	2
54	Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?. <i>Bone Marrow Transplantation</i> , 2013 , 48, 305	4.4	2
53	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 102, 2309; author reply 2309-10	2.2	2
52	Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT. <i>Blood</i> , 2019 , 134, 4018-4018	7.2	2
51	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2299-2305	4.7	2
50	Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
49	Salvage Therapy for Hodgkin Lymphoma: A Review of Current Regimens and Outcomes. <i>Journal of Blood Medicine</i> , 2020 , 11, 389-403	2.3	2
48	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 492.e1-492.e6		2

47	Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1876-1887	4.4	2
46	Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 478.e1-478.e5		2
45	Single-cell profiling reveals the dynamics of cytomegalovirus-specific T cells in haploidentical hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021 , 106, 2768-2773	6.6	2
44	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. <i>Bone Marrow Transplantation</i> , 2021 , 56, 883-889	4.4	2
43	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 999.e1-999.e1		2
42	Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2018 , 53, 366-370	4.4	1
41	T-Cell Replete Haploidentical Transplantation 2019 , 99-123		1
40	Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1246-7	4.4	1
39	Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 576-83	4.7	1
38	Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 417-20	1.9	1
37	Lymphomas. <i>Update on Cancer Therapeutics</i> , 2007 , 2, 101-110		1
36	Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide.. <i>Frontiers in Immunology</i> , 2021 , 12, 816231	8.4	1
35	Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study. <i>Blood</i> , 2018 , 132, 1655-1655	2.2	1
34	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis. <i>Blood</i> , 2018 , 132, 5748-5748	2.7	1
33	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT. <i>Blood</i> , 2019 , 134, 701-701	2.2	1
32	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 655-663	4.4	1
31	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020 , 11, 613954	8.4	1
30	THE EFFICACY OF IBRUTINIB IN PATIENTS WITH RELAPSED MANTLE CELL LYMPHOMA AFTER FIRST LINE INTENSIVE CHEMO-IMMUNOTHERAPY AND ASCT [A RETROSPECTIVE STUDY FROM THE LWP-EBMT. <i>Hematological Oncology</i> , 2019 , 37, 243-244	1.3	0

29	Intermediate-dose melphalan with stem-cell support in platinum-refractory ovarian cancer. <i>Bone Marrow Transplantation</i> , 2004 , 33, 1261-2	4.4	○
28	Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study.. <i>Blood</i> , 2009 , 114, 193-193	2.2	○
27	Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2017 , 130, 665-665	2.2	○
26	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2018 , 132, 4586-4586	2.2	○
25	Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres. <i>Blood</i> , 2018 , 132, 5692-5692	2.2	○
24	Comorbidities Index Is Not Predictive of Treatment Related Mortality in Patients (pts) Older Than 60 Years Treated with Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (RIC-ALLO).. <i>Blood</i> , 2009 , 114, 1180-1180	2.2	○
23	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1842-1849	4.4	○
22	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 912-912		○
21	Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report. <i>Transfusion and Apheresis Science</i> , 2013 , 49, 205-7	2.4	
20	Les cytokines: outils et cibles privilégiés dans l'immuno-surveillance du cancer. <i>Annales De L'institut Pasteur / Actualité</i> , 1998 , 9, 121-130		
19	High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients. <i>Annals of Oncology</i> , 2006 , 17, 719-20	10.3	
18	Lymphomas. <i>Update on Cancer Therapeutics</i> , 2006 , 1, 467-473		
17	Nonmyeloablative allogeneic peripheral-blood stem-cell transplantation in pancreatic adenocarcinoma: one case, high expectations. <i>Bone Marrow Transplantation</i> , 2004 , 33, 251	4.4	
16	Lymphomas. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 399-428		
15	Lymphomas. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005 , 391-399		
14	Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party. <i>Blood</i> , 2018 , 132, 484-484	2.2	
13	Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate. <i>Blood</i> , 2018 , 132, 2185-2185	2.2	
12	Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 1628-1628	2.2	

11	Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT. <i>Blood</i> , 2019 , 134, 3274-3274	2.2
10	Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients. <i>Blood</i> , 2019 , 134, 4625-4625	2.2
9	Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2019 , 134, 598-598	2.2
8	CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy. <i>Blood</i> , 2019 , 134, 4484-4484	2.2
7	Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma. <i>Blood</i> , 2019 , 134, 4614-4614	2.2
6	Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies. <i>Blood</i> , 2019 , 134, 4503-4503	2.2
5	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 328.e1-328.e6	
4	CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES. <i>Hematological Oncology</i> , 2019 , 37, 298-299	1.3
3	HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP. <i>Hematological Oncology</i> , 2019 , 37, 299-300	1.3
2	IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY). <i>Hematological Oncology</i> , 2019 , 37, 300-301	1.3
1	Allogeneic stem cell transplantation and non-myeloablative conditioning regimens. <i>Tumori</i> , 2000 , 86, 538-42	1.7